Risk sharing arrangements for pharmaceuticals: Potential considerations and recommendations for European payers

BMC Health Services Research

Volumn 10, Issue , 2010, Pages

  Adamski, Jakub ^a   Godman, Brian ^b,c,d   Ofierska Sujkowska, Gabriella ^e   Osiska, Bogusawa ^e   Herholz, Harald ^f   Wendykowska, Kamila ^g   Laius, Ott ^h   Jan, Saira ⁱ   Sermet, Catherine ^j   Zara, Corrine ^k   Kalaba, Marija ^l   Gustafsson, Roland ^b   Garuolienè, Kristina ^m   Haycox, Alan ^d   Garattini, Silvio ^c   Gustafsson, Lars L ^b  

^a Ministerstwo Zdrowia Poland   (Poland)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

^e Agency for Health Technology Assessment in Poland   (Poland)

^f Kassenärztliche Vereinigung in Hessen KVH   (Germany)

^g HTA CONSULTING   (Poland)

^h State Agency of Medicines   (Estonia)

ⁱ RUTGERS UNIVERSITY   (United States)

^j Institut de Recherche et de Documentation en Economie de la Santé Irdes   (France)

^k C Agy Hlth Technol Assess Res   (Spain)

^l Republic Institute for Health Insurance   (Serbia)

^m VILNIUS UNIVERSITY   (Lithuania)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DRUG INDUSTRY; ECONOMICS; EUROPE; HEALTH CARE PLANNING; HEALTH INSURANCE; HUMAN; METHODOLOGY; PHARMACY; REIMBURSEMENT; REVIEW; RISK MANAGEMENT;

DRUG INDUSTRY; EUROPE; HEALTH PLANNING GUIDELINES; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; PHARMACEUTICAL SERVICES; REIMBURSEMENT MECHANISMS; RISK SHARING, FINANCIAL;

EID: 77953066585     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-10-153     Document Type: Article

References (92)

1. Tier 4 drugs and the fraying of the social compact. T Lee E Emanuel, NEJM 2008 359 333 5 10.1056/NEJMp0804261 18650510
2. Recent national and regional drug reforms in Sweden - implications for pharmaceutical companies in Europe. B Wettermark B Godman K Andersson LL Gustafsson A Haycox V Bertele, Pharmacoeconomics 2008 26 537 50 10.2165/00019053-200826070-00001 18563945
3. Prices and distribution margins of in-patent drugs in pharmacy: A comparison in seven European countries. L Garattini N Motterlini D Cornago, Health Policy 2008 85 305 13 10.1016/j.healthpol.2007.08.005 17928092
4. Using effectiveness and cost-effectiveness to make drug coverage decisions - a comparison of Britain, Australia and Canada. F Clement A Harris JJ Li K Yong K Lee BJ Manns, JAMA 2009 302 1437 43 10.1001/jama.2009.1409 19809025
5. Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective. C McCabe L Bergmann N Bosanquet M Ellis H Enzmann M von Euler B Jönsson K-J Kallem D Newling V Nussler B Paschen R de Wilde N Wilking C Teale H Zwierzina, Annals of Oncology 2009 20 403 12 10.1093/annonc/mdn603 18854550
6. Enhancing the rational use of new medicines across European healthcare systems - A Position Paper. S Garattini V Bertele B Godman A Haycox B Wettermark L Gustafsson, Eur Jn Clinical Pharmacology 2008 64 1137 8 10.1007/s00228-008- 0537-z
7. Pharmaceutical risk-sharing agreements. J Cook J Vernon R Mannin, Pharmacoeconomics 2008 26 551 6 10.2165/00019053-200826070-00002 18563946
8. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden; global relevance. B Godman B Wettermark M Hoffman K Andersson A Haycox LL Gustafsson, Expert Rev Pharmacoeconomics Outcomes Res 2009 9 65 83 10.1586/14737167.9.1.65
9. How much good do new medicines do? Basic & Clin Pharm & Toxicology. A Walker C Booth A Brown K Paterson, 2009 105 Suppl 1 29
10. Access with evidence development schemes - a framework for description and evaluation. C McCabe T Stafinski R Edlin D Menon, Pharmacoeconomics 2010 28 143 52 10.2165/11530850-000000000-00000 20085390
11. Insight into recent reforms and initiatives in Austria; implications for key stakeholders. B Godman A Bucsics T Burkhardt A Haycox H Seyfried P Weininger, Expert Rev. Pharmacoeconomcis Outcomes Res 2008 8 357 71 10.1586/14737167.8.4.357
12. Having your cake and eating it: Office of Fair Trading proposal for funding new drugs to benefit patients and innovative companies. B Godman A Haycox U Schwabe R Joppi S Garattini, PharmacoEconomics 2008 26 91 8 10.2165/00019053-200826020-00001 18198930
13. Ongoing pharmaceutical reforms in France; considerations for other countries and implications for key stakeholder groups in France. C Sermet V Andrieu B Godman E Van Ganse A Haycox JP Reynier, Applied Health Economics and Health Policy 2010 8 7 24 20038190
14. Generic medicines from a societal perspective: Savings for healthcare systems? E Seeley P Kanavos, Eurohealth 2008 14 18 22
15. Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of Proton Pump Inhibitors and lipid-lowering drugs. B Godman U Schwabe G Selke B Wettermark, Pharmacoeconomics 2009 27 1 4 10.2165/00019053- 200927050-00010 19178119
16. Impact of recent reforms in Austria on utilisation and expenditure of PPIs and lipid lowering drugs; implications for the future. B Godman T Burkhardt A Bucsics B Wettermark P Weininger, Expert Rev Pharmacoeconomcis and Outcomes Research 2009 9 475 84 10.1586/erp.09.43
17. Working Group on Innovative Drugs. AIFA - Italian Medicines Agency, http://www.agenziafarmaco.it/allegati/integral-document.pdf Criteria for Ranking Therapeutic Innovation of New Drugs and Elements for Supplementing the Dossier for Admission to the Reimbursement System (document approved by the AIFACTS on July 10, 2007) (accessed 3 March 2010)
18. The pharmaceutical price regulation system: an OFT study. Office of Fair Trading (UK), Annexe K: International survey of pharmaceutical pricing and reimbursement schemes London: The Office of Fair Trading 2007 http://www.oft.gov.uk/shared-oft/reports/comp-policy/oft885k.pdf [online] [Accessed 3 March 2010]
19. Innovative approaches to pricing. Anon, IMS Pharma Pricing & Reimbursement 2007 224 227 http://www.imshealth.com/deployedfiles/imshealth/ Global/Content/StaticFile/Are-Traditional-Pricing-Models-Thing-of-Past.pdf (Accessed 3 March 2010)
20. Access with evidence development in the UK - past experience, current initiatives and future potential. A Briggs K Ritchie E Fenwick K Chalikidou P Littlejohns, Pharmacoeconomics 2010 28 163 70 10.2165/11531410-000000000-00000 20085392
21. Roche plans to address cost of Avastin in Europe. B Hirschler, 2008 http://uk.reuters.com/article/idUKL1834800720070418 (Accessed 3 March 2010)
22. Risk-sharing arrangements for innovative drugs. A new solution to old problems. G de Pourville, Eur J Health Econ 2006 7 155 7 10.1007/s10198-006- 0386-6 16912890
23. Cancer drugs costing 50 billion will crush the NHS, says expert. Anon, 2008 http://www.dailymail.co.uk/health/article-1053628/Cancer-drugs-costing- 50billion-crush-NHS-says-expert.html (Accessed 3 March 2010)
24. Bevacizumab in advanced cancer, too much or too little? A Jirillo F Vascon M Giacobbo, Annals of Oncology 2008 19 1817 8 10.1093/annonc/mdn564 18809585
25. Risk sharing and payment by results. A Breckenridge T Walley, Clin Pharmacol and Therapeutics 2008 83 666 7 10.1038/clpt.2008.15
26. No cure, no pay. C Møldrup, BMJ 2005 330 1262 4 10.1136/bmj.330.7502.1262 15920131
27. Setting up an outcomes guarantee for pharmaceuticals: New approach to risk sharing in primary care. S Chapman E Reeve G Rajaratnam R Neary, BMJ 2003 326 707 9 10.1136/bmj.326.7391.707 12663411
28. Setting the stage for risk-sharing agreements: International experiences and outcomes-based reimbursement. C Carapinha, SA Fam Pract 2008 50 62 5
29. NICE draft recommendation on the use of drugs for renal cancer. 2009/009. http://www.nice.org.uk/media/420/AD/2009009DraftNICEGuidanceDrugsRenalCancerv2. pdf [Accessed 3 March 2010]
30. Final NICE Kidney Cancer Guidance Recommends sunitinib. Medical News Today, 2009 http://www.medicalnewstoday.com/articles/143681.php [Accessed 3 March 2010]
31. Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy. NICE, 2009 http://www.nice.org.uk/ nicemedia/pdf/TA171GuidanceWord.doc [Accessed 3 March 2010]
32. UK's NICE approves lenalidomide in relapsed multiple myeloma. HemOnc today, 2009 http://www.hemonctoday.com/article.aspx?rid=41000 [Accessed 3 March 2010]
33. Transparency in pricing arrangements for medicines listed on the Australian Pharmaceutical Benefits Scheme. J Robertson E Walkom D Henry, Aust Health Rev 2009 33 192 9 10.1071/AH090192 19563308
34. Funding the unfundable - mechanisms for managing uncertainty in decisions on the introduction o new and innovative technologies into healthcare systems. T Stafinski C McCabe D Menon, Pharmacoeconomics 2010 28 113 42 10.2165/11530820-000000000-00000 20085389
35. New UK PPRS includes 3.9% price cut, flexible pricing and generic substitution. L Taylor, 2008 http://www.eatg.org/eatg/Global-HIV-News/Access-to- treatment/New-UK-PPRS-includes-3.9-price-cut-flexible-pricing-and-generic- substitution Accessed 3 March 2010)
36. Can't get no satisfaction? Will pay for performance help? Toward an economic framework for understanding performance-based risk sharing agreements for innovative medical products. A Towse L Garrison, Pharmacoeconomics 2010 28 93 102 10.2165/11314080-000000000-00000 20085386
37. Balancing Big Pharma's books. A Jack, BMJ 2008 336 418 9 10.1136/bmj.39491.469005.94 18292166
38. How much will Herceptin really cost? A Barrett T Riques M Small R Smith, BMJ 2006 333 1118 20 10.1136/bmj.39008.624051.BE 17124225
39. Access with evidence development - the US experience. P Mohr S Tunis, Pharmaceoeconomics 2010 28 153 62 10.2165/11531050-000000000-00000
40. Leader. Looking beyond the headlines. The Lancet Oncology 2007 8 561 10.1016/S1470-2045(07)70178-X 17613414
41. Patient access schemes for high-cost cancer medicines. S Williamson, Lancet 2010 11 111 2 10.1016/S1470-2045(09)70402-4
42. Pharmaceutical policies: effects of financial incentives for prescribers (Review). H Sturm A Austvoll-Dahlgren M Aaserud, et al. Cochrane database of Systematic Reviews 2007 3 Art No.: CD006731 DOI: 10.1002/14651858.CD006731
43. Pharmaceutical Pricing and Reimbursement Information, Belgium. A de Swaef Y Antonissen, 2007 http://ppri.oebig.at/Downloads/Results/Belgium-PPRI-2007.pdf (Accessed 3 March 2010)
44. Analysis of differences and commonalities in pricing and reimbursement systems in Europe. J Espín J Rovira, A study funded by DG Enterprise and Industry of the European Commission 2007 http://kce.docressources.info/opac/ index.php?lvl=notice-display&id=912 (Accessed 3 March 2010)
45. Pharmaceutical Pricing and Reimbursement Information, ESTONIA. K Pudersell A Vetka L Rootslane Mathiesen Mari, et al. 2007 http://ppri.oebig.at/ Downloads/Results/Estonia-PPRI-2007.pdf (Accessed 3 March 2010)
46. Health Systems in Transition. Estonia Health 2008 10 1 http://www.hpm.org/Downloads/reports/HiT-reports/Hit-Estonia-2008.pdf (Accessed 3 March 2010)
47. Drug price setting and regulation in France. N Grandfils, Working paper (DT number 16) 2008 http://www.irdes.fr/EspaceAnglais/Publications/ WorkingPapers/DT16DrugPriceSettingRegulationFrance.pdf (accessed 3 March 2010)
48. Healthcare Products Pricing Committee Annual Report. Comite Economique Des Produits De Sante, 2008 http://www.sante.gouv.fr/ceps/doc/rapport-activite- ceps-2008-anglais.pdf [Accessed 3 March 2010]
49. European Legal Developments Bulletin, 2007 19 2 17 19 spring
50. Pharmaceutical Pricing and Reimbursement Information, HUNGARY. T Kovcs P Rázsa S Szigeti, et al. 2007 http://ppri.oebig.at/Downloads/Results/ Hungary-PPRI-2007.pdf (Accessed 3 March 2010)
51. Pharmaceutical risk-sharing and conditional reimbursement in Italy. P Folino Gallo P Deambrosis, Krakow 2008 http://www.ceestahc.org/pliki/symp2008/ gallo.pdf (Accessed 3 March 2010)
52. Health Systems in Transition. P Barros J de Almeida Simes, 2007 9 5 Portugal: Health system review 2007 (Accessed 3 March 2010)
53. Pharmaceutical Pricing Reimbursement Information, Portugal. I Teixeira I Vieira, 2008 http://ppri.oebig.at/Downloads/Results/Portugal-PPRI-2008.pdf (Accessed 3 March 2010)
54. Cetuximab for first line treatment of metastatic colorectal cancer (MCRC). 2009 http://www.nice.org.uk/nicemedia/pdf/ ColorectalCancerCetuxamibACD2ManPAS.pdf [Accessed 3 March 2010]
55. Final NICE Kidney Cancer Guidance Recommends sunitinib. Medical News Today, 2009 http://www.medicalnewstoday.com/articles/143681.php [Accessed 3 March 2010]
56. Scottish Medicines Consortium - cetuximab, 100 mg/20 ml and 500 mg/100 ml solution for intravenous infusion. Anon, 2010 http://www.scottishmedicines.org. uk/files/ cetuximab%20Erbitux%20RESUBMISSION%20FINAL%20January%202010%20for%20website.pdf (Accessed 3 March 2010)
57. Final NICE Guidance Recommends Lucentis(R) (Ranibizumab) For Wet AMD in UK. Anon, Scrip News 2008 http://www.scripnews.com/news/nice-confirms-lucentis- choice-for-wet-amd-526 (Accessed 03 Jan 2010)
58. Costing statement: Ustekinumab for the treatment of adults with moderate to severe psoriasis. NICE, http://www.nice.org.uk/nicemedia/pdf/ TA180UstekinumabForTheTreatmentOfPsoriasisCostingStatement.pdf [Accessed 3 March 2010]
59. Scottish Medicines Consortium - ustekinumab 45 mg solution for injection. Anon, 2010 http://www.scottishmedicines.org.uk/files/ ustekinumab%20Stelara%20FINAL%20January%202010%20Amended%2004.02. 10%20for%20website.pdf (Accessed 28 February 2010)
60. Top of The Cancer Market? M Herper, 2006 http://www.forbes.com/2006/10/ 12/cancer-drug-pricing-biz-cz-mh-1012drugs.html (Accessed 3 March 2010) 16970374
61. Genentech Caps Cost of Cancer Drug for Some Patients. A Pollack, 2006 http://www.consumerwatchdog.org/patients/articles/?storyId=14384&bIndex=0 (Accessed 29 June 09)
62. Injectable claim edit (maximum dosage drug policy). United Healthcare, 2008 https://www.unitedhealthcareonline.com/ccmcontent/ProviderII/UHC/en-US/ Assets/ProviderStaticFiles/ProviderStaticFilesPdf/Clinician%20Resources/ Cancer%20Oncology/Injectable%20Drug%20March08%20NB%20Article.pdf (Accessed 3 March 2010)
63. Generic Biotech Products: Are the Floodgates Open? At Whose Expense?, Biotech Business. Anon, 2008 http://www.biotechnologyhealthcare.com/journal/ fulltext/3/4/BH0304022.pdf (3 March 2010)
64. Amgen Introduces Comprehensive Financial Assistance Programs for Cancer Patients. Amgen, http://findarticles.com/p/articles/mim0EIN/is-2006-Sept-27/ai- n16836635/ (Accessed 3 March 2010)
65. Sculptra Patient Access Program. Sanofi-Aventis, http://www.pparx.org/ resources/2008-05-19.SanofiAventis.Sculptra-Patient-Access-Program.3008.pdf [Accessed 3 March 2010]
66. Need Help Paying for TRUVADA? Gilead, http://www.truvada.com/pat400- paying-for-your-hiv-meds.aspx [Accessed 3 March 2010]
67. Free Prescription Drugs to Unemployed Courtesy of Pfizer, Inc. Carly Hart, 2009 http://www.associatedcontent.com/article/1747496/free-prescription- drugs-to-unemployed.html
68. Clozapine comes with money-back offer. P Anderson, http://www. mentalhealth.com/mag1/p51-cloz.html (accessed 3 March 2010)
69. Alzheimer's disease and acetylcholinesterase inhibitor agents: a two-year longitudinal study. C Fuschillo F Ascoli G Franzese F Campana C Cello M Galdi S La Pia C Cetrangolo, Arch Gerontol Geriatr Suppl 2004 9 187 94 10.1016/j.archger.2004.04.026 15207413
70. Results of a multi-level therapeutic approach for Alzheimer's disease subjects in the "real world" (CRONOS project): a 36-week follow-up study. G Bellelli E Lucchi N Minicuci L Rozzini A Bianchetti A Padovani M Trabucchi, Aging Clin Exp Res 2005 17 54 61 15847123
71. Final appraisal determination bortezomib monotherapy for relapsed multiple myeloma. Anon NICE, http://www.nice.org.uk/nicemedia/pdf/FAD.pdf (accessed 3 March 2010)
72. Satisfaction guaranteed - 'Payment by results' for biologic agents. A Garber M McCellan, NEJM 2007 357 1575 7 10.1056/NEJMp078204 17942870
73. Outcomes guarantee for lipid-lowering drugs: results from a novel approach to risk sharing in primary care. S Chapman E Reeve G Rajaratnam R Neary, Br J cardiol 2004 11 205 10
74. The Pharmaceutical Price regulation System - An OFT study. Office of Fair Trading (UK), 2007 http://www.oft.gov.uk (accessed 3 March 2010)
75. Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator. M Boggild J Palace P Barton Y Ben-Shlomo T Bregenezer C Dobson R Gray, BMJ 2009 339 4677 10.1136/bmj.b4677 19955128
76. No cure, no pay: an acceptable way of financing fertility treatments? Health Policy. G Haan F Rutten, 1989 13 239 49 10313425
77. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. JA Cramer A Benedict N Muszabek A Keskinaslan Z Khan, Int J Clin Pract 2008 62 76 87 10.1111/j.1742-1241.2007.01630.x 17983433
78. Soft Regulations in Pharmaceutical Policymaking: An Overview of Current Approaches and their Consequences. B Wettermark B Godman B Jacobsson F Haaijer-Ruskamp, Appl Econ Health Policy 2009 7 1 11
79. Doctors to pay for patients' medicine in Germany. R Hyde, Lancet 2007 370 1118 10.1016/S0140-6736(07)61494-9 17912769
80. Adherence to long-term therapies - Evidence for action. D Yack, http://www.who.int/chp/knowledge/publications/adherence-introduction.pdf WHO 2003 - WHO/MNC/03.01. (Accessed 3 March 2010)
81. Concordance, adherence and compliance in medicine taking. R Horne J Weinman N Barber, et al. NCCSDO 2005 http://www.npci.org.uk/adherence-to- medicines/atm/intro/resources/library-horne-final-report.pdf (Accessed 3 March 2010)
82. Impact of better adherence to statin agents in the primary prevention of coronary artery disease. S Perreault A Dragomir L Blais A Berrard L Lalonde M White D Pilon, Eur J Clin Pharmacol 2009 DOI 10.1007/s00228-009-0673-0 19529927
83. How can we regulate medicines better. S Garattini V Bertele', BMJ 2007 335 803 5 10.1136/bmj.39281.615706.94 17947785
84. Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures. G Apolone R Joppi V Bertele S Garattini, British Journal of Cancer 2005 93 504 9 10.1038/sj.bjc.6602750 16136026
85. The Italian Horizon Scanning project. R Joppi L Dematte AM Menti D Pase C Poggiani L Mezzalira, Eur J Clin Pharmacol 2009 (published online - DOI 10.1007/s00228-009-0666-z) 19495735
86. Value based pricing for NHS drugs: an opportunity not to be missed? K Claxton A Briggs M Buxton A Culyer C McCabe S Walke M Sculpher, BMJ 2008 336 252 4 10.1136/bmj.39434.500185.25
87. Evaluating promotional material from industry: an evidence-based approach. S Pegler J Underhill, Pharmaceutical Jn 2005 274 271 4
88. Fair pricing for medicines in the UK. T Walley, Expert Rev Pharmacoeconomics and Outcomes Res 2007 7 207 9 10.1586/14737167.7.3.207
89. Value-based pricing of drugs in the UK. D Webb A Walker, Lancet 2007 369 1415 6 10.1016/S0140-6736(07)60648-5 17467498
90. Neuropsychotherapeutics in the UK; what has been the impact of NICE? CNS Drugs. T Walley, 2004 18 1 12 14731055
91. Current National Initiatives Policies to control drug costs in Europe: UK perspective. M Duerden N Gogna B Godman K Eden M Mallinson, J Ambulatory Care Manage 2004 27 132 8 15069991
92. Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis. S Sudlow C Counsel, BMJ 2003 326 288 92 10.1136/bmj.326.7385.388